We further used a genome-wide CRISPR/Cas9 screen to identify vulnerabilities of YAP1/TAZ-driven melanoma cell lines and validated a sulfate transporter as an attractive therapeutic target whose inhibition overcomes YAP1/TAZ-driven mechanisms of MAPKi resistance. Here, YAP1 is linked to melanoma.